Zobrazeno 1 - 10
of 47
pro vyhledávání: ''
Autor:
Joao Victor Machado Alessi, Biagio Ricciuti, Greg Jones, Gonzalo Recondo, Mizuki Nishino, Tim Forshew, Michael Cheng, Mariano Severgnini, Marissa N. Lawrence, Christine A. Lydon, Mark M. Awad
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
BackgroundCurrently available biomarkers are imperfect in their ability to predict responses to the multiple first-line treatment options available for patients with advanced non-small cell lung cancer (NSCLC). Having an early pharmacodynamic marker
Autor:
David R. Gandara, S. Morris, A. Cardona, Julien Mazieres, Martin Reck, Marcus Ballinger, Diana Mendus, Denis Moro-Sibilot, Shirish M. Gadgeel, Achim Rittmeyer, Solange Peters
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for immunotherapy of cancer, vol 9, iss 3
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 3
Journal for Immunotherapy of Cancer
BackgroundTreatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in randomized phase III studies because it requires two pretreatment scans. This study aimed to dev
Autor:
Jorge Arturo Alatorre-Alexander, Hina Patel, Kerstin Trunzer, Delvys Rodriguez-Abreu, Jinming Yu, T. Newsom-Davis, Andrea Ardizzoni, Konstantinos N. Syrigos, A. Cardona, Pablo D Perez-Moreno, Jonathan Tolson, Sergio J. Azevedo, Hans J.M. Smit, Belen Rubio-Viqueira
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAtezolizumab treatment improves survival, with manageable safety, in patients with previously treated advanced/metastatic non-small cell lung cancer. The global phase III/IV study TAIL (NCT03285763) was conducted to evaluate the safety and
Autor:
Gang Chen, Hong Yang, Xin Yi, Yunpeng Yang, Yaxiong Zhang, Zhesheng Wen, Xuefeng Xia, Yanfang Guan, Zhonghan Zhang, Lanjun Zhang, Ningning Zhou, Yan Huang, Yuxiang Ma, Yuanyuan Zhao, Junye Wang, Hui Pan, Shaodong Hong, Hao-Xian Yang, Hao Long, Hongyun Zhao, Jianhua Zhan, Xue Hou, Qiufan Zheng, Xi Chen, Lianpeng Chang, Li Zhang, Huaqiang Zhou, Shen Zhao, Wenfeng Fang, Ting Zhou, Aiwei Wu, Xin Wang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
High-level tissue tumor mutational burden (tTMB) or blood TMB (bTMB) are associated with better response of immunotherapy in non-small cell lung cancer (NSCLC) patients. However, the correlations of single-region tTMB, multi-region tTMB and bTMB rema
Autor:
Daniel E. Carvajal-Hausdorf, Vamsidhar Velcheti, Scott N. Gettinger, Mehmet Altan, Kurt A. Schalper, David L. Rimm, Roy S. Herbst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Small cell lung cancer (SCLC) accounts for 10–15% of all lung malignancies and its prognosis is dismal. Although early studies have shown promising clinical activity of immune checkpoint blockers, the immune composition and expression of
Autor:
Qingfeng Zhu, Haidan Guo, Franco Verde, Hao Wang, Patrick M. Forde, Dung T. Le, Sune Justesen, Teniola Oke, Hongni Fan, Prerna Suri, Leslie Cope, Ludmila Danilova, Janis M. Taube, Anas H. Awan, Franck Housseau, Jennifer N. Durham, Hok Yee Chan, Nickolas Papadopoulos, Elizabeth D. Thompson, Bjarne Bartlett, Robert A. Anders, Nicholas Siegel, Victor E. Velculescu, Kellie N. Smith, John-William Sidhom, Laveet K. Aulakh, Kristen A. Marrone, Valsamo Anagnostou, Cynthia L. Sears, Joanne Riemer, Drew M. Pardoll, Luis A. Diaz, Brandon Luber, Ada J. Tam, Bert Vogelstein, Tricia R. Cottrell, Nicolas J. Llosa, Kenneth W. Kinzler, Julie R. Brahmer, William H. Sharfman, Jarushka Naidoo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor mu
Autor:
Calum MacAulay, Erin A. Marshall, John C. English, Sonia H. Y. Kung, Katey S. S. Enfield, Stephen Lam, Spencer D. Martin, Zhaoyang Chen, Paul Gallagher, Brad H. Nelson, Katy Milne, Martial Guillaud, Wan L. Lam
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background The tumor microenvironment (TME) is a complex mixture of tumor epithelium, stroma and immune cells, and the immune component of the TME is highly prognostic for tumor progression and patient outcome. In lung cancer, anti-PD-1 therapy signi
Autor:
Ami A. Shah, Laura C. Cappelli, Geoffrey T. Gibney, Clifton O. Bingham, Patrick M. Forde, William H. Sharfman, Evan J. Lipson, Jarushka Naidoo, Michael A. Carducci, Kendall F. Moseley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-9 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background The use of immune checkpoint inhibitors is increasing in cancer therapy today. It is critical that treatment teams become familiar with the organ systems potentially impacted by immune-related adverse events associated with these drugs. He
Autor:
Roger Llatjós, Ernest Nadal, David Cordero, Adriana Lopez-Doriga, Ricard Ramos, Victor Moreno, Ramon Palmero, Xavier Solé, Susana Padrones, Sara Hijazo-Pechero, Ania Alay, Ignacio Escobar, Elisabet Aliagas, Raúl Marín
Publikováno v:
Journal for Immunotherapy of Cancer
Dipòsit Digital de la UB
Universidad de Barcelona
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Dipòsit Digital de la UB
Universidad de Barcelona
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
BackgroundMalignant pleural mesothelioma (MPM) is a rare and aggressive neoplasia affecting the lung mesothelium. Immune checkpoint inhibitors (ICI) in MPM have not been extremely successful, likely due to poor identification of suitable candidate pa
Autor:
Ronny Ben-Avi, Abdullah El-Sayes, Ali A. Ashkar, Ana L. Portillo, Marianne V. Chew, Yaron Shargall, Sophie M. Poznanski, Isabella Y. Fan, Eduardo A. Rojas, Tyrah M. Ritchie
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Lung cancer remains the leading cause of cancer death worldwide despite the significant progress made by immune checkpoint inhibitors, including programmed death receptor-1 (PD1)/PD ligand 1 (PDL1)-blockade therapy. PD1/PDL1−blockade has achieved u